drugset / Trial / NCT04922567
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Phase 2
Recruiting
289 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Changhai Hospital · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabFirst Affiliated Hospital of Harbin Medical University · collabFirst Hospital of China Medical University · collabHenan Provincial People's Hospital · collabHuashan Hospital · collabHunan Cancer Hospital · collabJilin Provincial Tumor Hospital · collabRenJi Hospital · collabRuijin Hospital · collabShandong Provincial Hospital · collabShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collabShanxi Province Cancer Hospital · collabSouthern Medical University, China · collabThe Affiliated Hospital of Xuzhou Medical University · collabThe First Affiliated Hospital of Anhui Medical University · collabThe First Affiliated Hospital of Dalian Medical University · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabUnion hospital of Fujian Medical University · collabXiangya Hospital of Central South University · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collabXinqiao Hospital of Chongqing · collabZhongda Hospital · collabZhongshan Hospital Xiamen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)
Timeline
- Start
- 2021-04-01
- Primary completion
- 2023-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 100 mg | Oral |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |